• Sales of A$16.7 million (US$11 million) for the 6 months ended 31 December 2025 were up 31% (in constant currency) on the prior comparative period
• Substantially improved EBITDA by A$2.0 million to A$2.2 million for 6 months ended 31 December 2025
• Positive EBITDA achieved in December 2025, consistent with guidance

Nova Eye Medical Limited (ASX: EYE) is pleased to announce H1FY26 (six months to 31 December 2025) financial results. The Company achieved record half-year revenue of US$11 million (A$16.7 million), representing 31% growth on the prior year in constant currency. This reflects continued momentum in the United States and expanding sales outside the USA. The Company's revenues for the last 12 months increased to A$32.2 million (~US$21 million), representing 24% year-on-year growth, approximately three times estimated industry growth. The EBITDA loss for H1FY26 was A$2.2 million (US$1.4 million), compared with A$4.2 million (US$2.8 million) in the prior comparative period. This improvement was driven by significant gross margin improvement and operating leverage. Positive EBITDA was achieved in December 2025, consistent with Company guidance. Cash outflow from operations for H1FY26 was A$2.2 million, of which A$1 million related to investment in working capital, resulting in an underlying cash outflow for operations of A$1.2 million. There was a positive underlying cash flow from operations (after working capital investment) of A$0.2 million for the 3 months to December 2025.

Sales revenue (excluding China): US$21 - 24 million (A$32 - 37 million) implies a minimum 21% growth and mid guidance growth of 30%. Targeting breakeven EBITDA in H2FY26.